|Bid||5.05 x 1300|
|Ask||5.71 x 1300|
|Day's Range||5.45 - 5.68|
|52 Week Range||5.45 - 21.48|
|Beta (5Y Monthly)||1.72|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 09, 2022 - Mar 14, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||22.17|
BEDFORD, Mass., January 18, 2022--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that AffaMed Therapeutics dosed its first patient in a real-world setting study being conducted in China evaluating the safety and efficacy of DEXTENZA® (0.4 mg dexamethasone ophthalmic insert) for the treatment of ocular inflammation and pain post-catara
Tokyo, M0, based Investment company Hikari Power Ltd (Current Portfolio) buys Alphabet Inc, Vanguard Health Care ETF, Bristol-Myers Squibb Co, Jack Henry & Associates Inc, Parker Hannifin Corp, sells Anheuser-Busch InBev SA/NV, The Kraft Heinz Co, Amarin Corp PLC, ADMA Biologics Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Hikari Power Ltd.
BEDFORD, Mass., January 04, 2022--Ocular Therapeutix, Inc. (Nasdaq: OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will present at the H.C. Wainwright BioConnect 2022 Virtual Conference being held January 10-13, 2022.